查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1941816

疫苗市场规模、份额和趋势分析报告：按适应症、类型、给药途径、年龄层、分销管道、地区和细分市场预测（2026-2033 年）

Vaccine Market Size, Share & Trends Analysis Report By Indication, By Type, By Route Of Administration, By Age Group, By Distribution Channel, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

疫苗市场概况

2025年全球疫苗市场规模估计为727.5亿美元，预计2033年将达到1,157.7亿美元。

预计从 2026 年到 2033 年，市场将以 5.78% 的复合年增长率成长。这一增长是由研发投入的增加以及赞助商和研究人员对降低研发成本日益增长的兴趣所推动的。

此外，包括製药和生技公司在内的终端用户越来越多地采用外包实验室服务以降低研发活动的总体成本，这也推动了预测期内的市场成长。全球疫苗产业被视为医疗保健系统的重要组成部分，其主要驱动力来自地方公共卫生免疫规划、感染疾病防范和常规疾病预防措施。疫苗已被纳入国家医疗保健预算和长期公共卫生计划，因为它们有助于减轻疾病负担和降低后续治疗成本。根据世界卫生组织（世卫组织）估计，透过预防麻疹、白喉、破伤风、百日咳和流感等疫苗可预防疾病，免疫接种每年可在全球预防约200万至300万人死亡。 2024年4月，世卫组织在医学期刊《采血针》上发表了一项综合分析报告，指出全球免疫规划在过去50年中已预防了约1.54亿人死亡。这进一步证实了疫苗接种是公共卫生领域的核心投资。 2025年4月，世界卫生组织设立“世界免疫週”，专注于消除免疫接种差距、加强免疫接种服务体係以及提高终身疫苗接种率。这体现了全球政策持续将免疫接种作为核心公共卫生措施的优先事项。

市场成长的驱动因素包括感染疾病的持续蔓延、成人和老年人免疫接种计划的扩大，以及疫情相关中断后常规免疫接种覆盖率的恢復。根据世界卫生组织（世卫组织）发布的《2024年全球结核病报告》，预计2023年全球将有1080万人患有结核病，其中东南亚和非洲等地区的结核病负担最为沉重，这表明高负担市场对预防和应对策略的需求持续存在。世卫组织于2024年4月发布的《全球肝炎报告》估计，全球约有2.54亿人患有慢性B型肝炎，5,000万人患有慢性C型肝炎，每年新增病毒性肝炎感染病例超过100万例。这显示肝炎仍然是全球持续存在的公共卫生负担。 2025年5月，美国食品药物管理局（FDA）核准了Moderna公司研发的下一代新冠疫苗mNEXSPIKE，用于65岁及以上的老年人和12至64岁患有基础疾病的人。这显示监管机构持续支持在高风险族群中推广疫苗接种。

市场格局日益受到技术平台、产品系列和生产策略转变的影响，反映出疫苗正朝着更广泛的疾病覆盖范围和长期供应韧性的方向发展。基于平台的开发方法，特别是mRNA技术，能够加快设计週期，提高抗原选择的柔软性，并促进联合疫苗的研发，从而支持产品组合扩展到单一疾病产品之外。这些进步促使人们更加关注呼吸系统疾病的适应症和多病原体预防策略，尤其是在成人和老年人群中。 2022年9月，辉瑞和BioNTech启动了基于mRNA的流感疫苗的III期临床试验，显示mRNA平台的应用范围已扩展到COVID-19以外的领域。 2025年5月，世界卫生组织（WHO）报告称，其mRNA技术转移计画已扩展至15个全球合作伙伴，支持疫苗生产的分散化和区域生产能力的建设。同时，成人免疫框架的扩展和更广泛的监管建议正在扩大疫苗的目标市场，涵盖所有年龄层。这表明，市场演变并非由短期需求波动所驱动，而是由公共部门优先事项、平台多元化和人口结构变化所驱动。

目录

第一章：调查方法和范围

第二章执行摘要

第三章：疫苗市场的变数、趋势和范围

  • 市场体系展望
  • 市场动态
  • 商业环境分析
    • 产业分析—波特五力分析
    • PESTLE分析
    • 管道分析
    • 专利到期分析
    • 定价分析

第四章：疫苗市场：依适应症分類的业务分析

  • 按适应症分類的市场份额（2025 年和 2033 年）
  • 按适应症分類的市场规模、预测和趋势分析（2021-2033 年）
  • 病毒疫苗
  • 细菌疫苗
  • 癌症疫苗
  • 过敏疫苗
  • 其他的

第五章：疫苗市场：按类型分類的业务分析

  • 按类型分類的市场份额（2025 年和 2033 年）
  • 按类型分類的市场规模、预测和趋势分析（2021-2033 年）
  • 次单位疫苗
  • 失活
  • 减毒活病毒疫苗
  • mRNA疫苗
  • 病毒载体疫苗

第六章：疫苗市场：按给药途径分類的业务分析

  • 按给药途径分類的市场份额（2025 年和 2033 年）
  • 按给药途径分類的市场规模、预测和趋势分析（2021-2033 年）
  • 口服
  • 注射
  • 鼻内

第七章：疫苗市场：依年龄组别分類的业务分析

  • 按年龄组别分類的市场份额（2025 年和 2033 年）
  • 按年龄组别分類的市场规模、预测和趋势分析（2021-2033 年）
  • 儿童
  • 成人

第八章：疫苗市场：按分销管道分類的业务分析

  • 按分销管道分類的市场份额（2025 年和 2033 年）
  • 按分销管道分類的市场规模、预测和趋势分析（2021-2033 年）
  • 医院和零售药局
  • 政府供应商
  • 其他的

第九章：疫苗市场：区域预测与趋势分析

  • 区域市场占有率分析（2025 年和 2033 年）
  • 区域市场概览
  • 市场规模及预测趋势分析（2021-2033）：
  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 挪威
    • 瑞典
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第十章 竞争格局

  • 参与公司概况
  • 企业市场分析
  • 公司分类
  • 策略规划
  • 公司简介/列表
    • Serum Institute of India Pvt. Ltd.
    • Seqirus
    • Sanofi
    • Merck &Co., Inc.
    • Pfizer Inc.
    • Moderna Inc.
    • Sinovac
    • BioNTech SE
    • AstraZeneca
Product Code: 978-1-68038-990-6

Vaccine Market Summary

The global vaccine market size was estimated at USD 72.75 billion in 2025 and is projected to reach USD 115.77 billion by 2033, growing at a CAGR of 5.78% from 2026 to 2033. The market is driven by the increasing investment in R&D and the rising focus of sponsors & investigators on reducing research costs.

Moreover, the increasing adoption of outsourcing laboratory services by pharmaceutical & biotechnology companies and other end users to reduce the overall cost of research activities further supports the market growth over the forecast period. The global vaccine industry is positioned as a strategic component of preventive healthcare systems and is primarily driven by public immunization programs, outbreak preparedness, and routine disease prevention initiatives across regions. Vaccines are integrated into national healthcare budgets and long-term public health planning due to their role in reducing disease burden and downstream treatment costs. According to the World Health Organization, immunization prevents an estimated 2-3 million deaths every year worldwide by protecting against vaccine-preventable diseases such as measles, diphtheria, tetanus, pertussis, and influenza. In April 2024, the WHO published a comprehensive analysis in The Lancet reporting that global immunization programs have prevented approximately 154 million deaths over the past 50 years, reinforcing vaccination as a central public health investment. In April 2025, the World Health Organization marked World Immunization Week with a focus on closing immunization gaps, strengthening immunization delivery systems, and expanding vaccine coverage across the life course, reflecting continued global policy prioritization of immunization as a core public health intervention.

Market growth is supported by the continued prevalence of infectious diseases, expansion of adult and geriatric immunization programs, and recovery of routine vaccination coverage following pandemic-related disruptions. According to the World Health Organization Global Tuberculosis Report 2024, an estimated 10.8 million people developed tuberculosis globally in 2023, with the highest burden concentrated in regions such as Southeast Asia and Africa, sustaining demand for preventive and control strategies in high-burden markets. In April 2024, the World Health Organization Global Hepatitis Report estimated that approximately 254 million people were living with chronic hepatitis B and 50 million with chronic hepatitis C worldwide, with more than 1 million new viral hepatitis infections occurring each year, underscoring the continued public health burden of hepatitis globally. In May 2025, the U.S. Food and Drug Administration approved Moderna's next-generation COVID-19 vaccine, mNEXSPIKE, for older adults aged 65 years and above and for individuals aged 12-64 years with underlying medical conditions, indicating continued regulatory support for vaccine adoption among high-risk populations.

The market is increasingly shaped by shifts in technology platforms, product portfolios, and manufacturing strategies, reflecting a transition toward broader disease coverage and long-term supply resilience. Platform-based development approaches, particularly mRNA technologies, have enabled faster design cycles, greater flexibility in antigen selection, and the development of combination vaccines, supporting portfolio expansion beyond single-disease products. These advancements are contributing to increased focus on respiratory indications and multi-pathogen prevention strategies, particularly within adult and elderly populations. In September 2022, Pfizer and BioNTech initiated Phase III clinical trials for an mRNA-based influenza vaccine, marking the extension of mRNA platforms beyond COVID-19 applications. In May 2025, the World Health Organization reported that its mRNA Technology Transfer Programme had expanded to 15 global partners, supporting the decentralization of vaccine manufacturing and the development of regional production capacity. In parallel, expanding adult immunization frameworks and broader regulatory recommendations are increasing the addressable market for vaccines across age groups, indicating that market evolution is being driven by public-sector priorities, platform diversification, and demographic shifts rather than short-term demand fluctuations.

Global Vaccine Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global vaccine market report based on indication, type, route of administration, age group, distribution channel, and region:

  • Indication Outlook (Revenue, USD Million, 2021 - 2033)
  • Viral Vaccines
    • Hepatitis
    • Pediatric (Children)
    • Adult
    • Influenza
    • Pediatric (Children)
    • Adult
    • HPV
    • Pediatric (Children)
    • Adult
    • MMR
    • Pediatric (Children)
    • Adult
    • Rotavirus
    • Pediatric (Children)
    • Adult
    • Herpes Zoster
    • Pediatric (Children)
    • Adult
    • Japanese Encephalitis
    • Pediatric (Children)
    • Adult
    • RSV
    • Pediatric (Children)
    • Adult
    • Others
    • Pediatric (Children)
    • Adult
  • Bacterial Vaccines
    • Meningococcal Diseases
    • Pediatric (Children)
    • Adult
    • Pneumococcal diseases
    • Pediatric (Children)
    • Adult
    • DPT
    • Pediatric (Children)
    • Adult
    • Others
    • Pediatric (Children)
    • Adult
  • Cancer Vaccines
    • Pediatric (Children)
    • Adult
  • Allergy Vaccines
    • Pediatric (Children)
    • Adult
  • Other
    • Pediatric (Children)
    • Adult
  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Subunit Vaccines
    • Recombinant Vaccines
    • Conjugate Vaccines
    • Toxoid Vaccines
  • Inactivated
  • Live Attenuated
  • mRNA Vaccines
  • Viral Vector Vaccines
  • Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
  • Oral
  • Parenteral
  • Nasal
  • Age Group Outlook (Revenue, USD Million, 2021 - 2033)
  • Pediatric
  • Adult
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Hospital & Retail Pharmacies
  • Government Suppliers
  • Others
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1 Market Segmentation & Scope
  • 1.2 Segment Definitions
    • 1.2.1 Indication
    • 1.2.2 Type
    • 1.2.3 Route of Administration
    • 1.2.4 Age Group
    • 1.2.5 Distribution Channel
  • 1.3 Estimates and Forecast Timeline
  • 1.4 Research Methodology
  • 1.5 Information Procurement
    • 1.5.1 Purchased Database
    • 1.5.2 GVR's Internal Database
    • 1.5.3 Secondary Sources
    • 1.5.4 Primary Research
  • 1.6 Information Analysis
    • 1.6.1 Data Analysis Models
  • 1.7 Market Formulation & Data Visualization
  • 1.8 Model Details
    • 1.8.1 Commodity Flow Analysis
  • 1.9 List of Secondary Sources
  • 1.10 Objectives

Chapter 2. Executive Summary

  • 2.1 Market Snapshot
  • 2.2 Segment Snapshot
  • 2.3 Competitive Landscape Snapshot

Chapter 3. Vaccine Market Variables, Trends, & Scope

  • 3.1 Market Lineage Outlook
  • 3.2 Market Dynamics
    • 3.2.1 Market Driver Analysis
    • 3.2.2 Market Restraint Analysis
  • 3.3 Business Environment Analysis
    • 3.3.1 Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1 Supplier Power
      • 3.3.1.2 Buyer Power
      • 3.3.1.3 Substitution Threat
      • 3.3.1.4 Threat of New Entrants
      • 3.3.1.5 Competitive Rivalry
    • 3.3.2 PESTLE Analysis
    • 3.3.3 Pipeline Analysis
    • 3.3.4 Patent Expiry Analysis
    • 3.3.5 Pricing Analysis

Chapter 4. Vaccine Market: Indication Business Analysis

  • 4.1. Indication Market Share, 2025 & 2033
  • 4.2. Indication Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Million)
  • 4.4. Viral Vaccines
    • 4.4.1 Viral Vaccine Market, 2021 - 2033 (USD Million)
      • 4.4.1.1 Hepatitis Market, 2021 - 2033 (USD Million)
        • 4.4.1.1.1 Pediatric (Children) Market, 2021 - 2033 (USD Million)
        • 4.4.1.1.2 Adult Market, 2021 - 2033 (USD Million)
      • 4.4.1.2 Influenza Market, 2021 - 2033 (USD Million)
        • 4.4.1.2.1 Pediatric (Children) Market, 2021 - 2033 (USD Million)
        • 4.4.1.2.2 Adult Market, 2021 - 2033 (USD Million)
      • 4.4.1.3 HPV Market, 2021 - 2033 (USD Million)
        • 4.4.1.3.1 Pediatric (Children) Market, 2021 - 2033 (USD Million)
        • 4.4.1.3.2 Adult Market, 2021 - 2033 (USD Million)
      • 4.4.1.4 MMR Market, 2021 - 2033 (USD Million)
        • 4.4.1.4.1 Pediatric (Children) Market, 2021 - 2033 (USD Million)
        • 4.4.1.4.2 Adult Market, 2021 - 2033 (USD Million)
      • 4.4.1.5 Rotavirus Market, 2021 - 2033 (USD Million)
        • 4.4.1.5.1 Pediatric (Children) Market, 2021 - 2033 (USD Million)
        • 4.4.1.5.2 Adult Market, 2021 - 2033 (USD Million)
      • 4.4.1.6 Herpes Zoster Market, 2021 - 2033 (USD Million)
        • 4.4.1.6.1 Pediatric (Children) Market, 2021 - 2033 (USD Million)
        • 4.4.1.6.2 Adult Market, 2021 - 2033 (USD Million)
      • 4.4.1.7 Japanese Encephalitis Market, 2021 - 2033 (USD Million)
        • 4.4.1.7.1 Pediatric (Children) Market, 2021 - 2033 (USD Million)
        • 4.4.1.7.2 Adult Market, 2021 - 2033 (USD Million)
      • 4.4.1.8 RSV Market, 2021 - 2033 (USD Million)
        • 4.4.1.8.1 Pediatric (Children) Market, 2021 - 2033 (USD Million)
        • 4.4.1.8.2 Adult Market, 2021 - 2033 (USD Million)
      • 4.4.1.9 Others Market, 2021 - 2033 (USD Million)
        • 4.4.1.9.1 Pediatric (Children) Market, 2021 - 2033 (USD Million)
        • 4.4.1.9.2 Adult Market, 2021 - 2033 (USD Million)
  • 4.5. Bacterial Vaccines
    • 4.5.1 Bacterial Vaccine Market, 2021 - 2033 (USD Million)
      • 4.5.1.1 Meningococcal Diseases Market, 2021 - 2033 (USD Million)
      • 4.5.1.2 Pneumococcal diseases Market, 2021 - 2033 (USD Million)
      • 4.5.1.3 DPT Market, 2021 - 2033 (USD Million)
      • 4.5.1.4 Others Market, 2021 - 2033 (USD Million)
  • 4.6. Cancer Vaccines
    • 4.6.1 Cancer Vaccine Market, 2021 - 2033 (USD Million)
      • 4.6.1.1 Pediatric (Children) Market, 2021 - 2033 (USD Million)
      • 4.6.1.2 Adult Market, 2021 - 2033 (USD Million)
  • 4.7. Allergy Vaccines
    • 4.7.1 Allergy Vaccine Market, 2021 - 2033 (USD Million)
      • 4.7.1.1 Pediatric (Children) Market, 2021 - 2033 (USD Million)
      • 4.7.1.2 Adult Market, 2021 - 2033 (USD Million)
  • 4.8. Other
    • 4.8.1 Other Market, 2021 - 2033 (USD Million)
      • 4.8.1.1 Pediatric (Children) Market, 2021 - 2033 (USD Million)
      • 4.8.1.2 Adult Market, 2021 - 2033 (USD Million)

Chapter 5. Vaccine Market: Type Business Analysis

  • 5.1. Type Market Share, 2025 & 2033
  • 5.2. Type Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
  • 5.4. Subunit Vaccines
    • 5.4.1 Subunit Vaccine Market, 2021 - 2033 (USD Million)
      • 5.4.1.1 Recombinant Vaccine Market, 2021 - 2033 (USD Million)
      • 5.4.1.2 Conjugate Vaccine Market, 2021 - 2033 (USD Million)
      • 5.4.1.3 Toxoid Vaccine Market, 2021 - 2033 (USD Million)
  • 5.5. Inactivated
    • 5.5.1 Inactivated Market, 2021 - 2033 (USD Million)
  • 5.6. Live Attenuated
    • 5.6.1 Live Attenuated Market, 2021 - 2033 (USD Million)
  • 5.7. mRNA Vaccines
    • 5.7.1 mRNA Vaccine Market, 2021 - 2033 (USD Million)
  • 5.8. Viral Vector Vaccines
    • 5.8.1 Viral Vector Vaccine Market, 2021 - 2033 (USD Million)

Chapter 6. Vaccine Market: Route of Administration Business Analysis

  • 6.1. Route of Administration Market Share, 2025 & 2033
  • 6.2. Route of Administration Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2021 to 2033 (USD Million)
  • 6.4. Oral
    • 6.4.1 Oral Market, 2021 - 2033 (USD Million)
  • 6.5. Parenteral
    • 6.5.1 Parenteral Market, 2021 - 2033 (USD Million)
  • 6.6. Nasal
    • 6.6.1 Nasal Market, 2021 - 2033 (USD Million)

Chapter 7. Vaccine Market: Age Group Business Analysis

  • 7.1. Age Group Market Share, 2025 & 2033
  • 7.2. Age Group Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by Age Group, 2021 to 2033 (USD Million)
  • 7.4. Pediatric
    • 7.4.1 Pediatric Market, 2021 - 2033 (USD Million)
  • 7.5. Adult
    • 7.5.1 Adult Market, 2021 - 2033 (USD Million)

Chapter 8. Vaccine Market: Distribution Channel Business Analysis

  • 8.1. Distribution Channel Market Share, 2025 & 2033
  • 8.2. Distribution Channel Segment Dashboard
  • 8.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Million)
  • 8.4. Hospital & Retail Pharmacies
  • 8.5. Government Suppliers
    • 8.5.1 Government Suppliers Market, 2021 - 2033 (USD Million)
  • 8.6. Others
    • 8.6.1 Others Market, 2021 - 2033 (USD Million)

Chapter 9. Vaccine Market: Regional Estimates & Trend Analysis

  • 9.1 Regional Market Share Analysis, 2025 & 2033
  • 9.2 Regional Market Dashboard
  • 9.3 Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 9.4 North America
    • 9.4.1 North America Vaccine Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 9.4.2 U.S.
      • 9.4.2.1 Key Country Dynamics
      • 9.4.2.2 Regulatory Framework
      • 9.4.2.3 Pricing Analysis
      • 9.4.2.4 U.S. Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.4.3 Canada
      • 9.4.3.1 Key Country Dynamics
      • 9.4.3.2 Regulatory Framework
      • 9.4.3.3 Pricing Analysis
      • 9.4.3.4 Canada Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.4.4 Mexico
      • 9.4.4.1 Key Country Dynamics
      • 9.4.4.2 Regulatory Framework
      • 9.4.4.3 Pricing Analysis
      • 9.4.4.4 Mexico Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5 Europe
    • 9.5.1 Europe Vaccine Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 9.5.2 UK
      • 9.5.2.1 Key Country Dynamics
      • 9.5.2.2 Regulatory Framework
      • 9.5.2.3 Pricing Analysis
      • 9.5.2.4 UK Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.3 Germany
      • 9.5.3.1 Key Country Dynamics
      • 9.5.3.2 Regulatory Framework
      • 9.5.3.3 Pricing Analysis
      • 9.5.3.4 Germany Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.4 France
      • 9.5.4.1 Key Country Dynamics
      • 9.5.4.2 Regulatory Framework
      • 9.5.4.3 Pricing Analysis
      • 9.5.4.4 France Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.5 Italy
      • 9.5.5.1 Key Country Dynamics
      • 9.5.5.2 Regulatory Framework
      • 9.5.5.3 Pricing Analysis
      • 9.5.5.4 Italy Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.6 Spain
      • 9.5.6.1 Key Country Dynamics
      • 9.5.6.2 Regulatory Framework
      • 9.5.6.3 Pricing Analysis
      • 9.5.6.4 Spain Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.7 Denmark
      • 9.5.7.1 Key Country Dynamics
      • 9.5.7.2 Regulatory Framework
      • 9.5.7.3 Pricing Analysis
      • 9.5.7.4 Denmark Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.8 Norway
      • 9.5.8.1 Key Country Dynamics
      • 9.5.8.2 Regulatory Framework
      • 9.5.8.3 Pricing Analysis
      • 9.5.8.4 Norway Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.9 Sweden
      • 9.5.9.1 Key Country Dynamics
      • 9.5.9.2 Regulatory Framework
      • 9.5.9.3 Pricing Analysis
      • 9.5.9.4 Sweden Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6 Asia Pacific
    • 9.6.1 Asia Pacific Vaccine Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 9.6.2 Japan
      • 9.6.2.1 Key Country Dynamics
      • 9.6.2.2 Regulatory Framework
      • 9.6.2.3 Pricing Analysis
      • 9.6.2.4 Japan Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.6.3 China
      • 9.6.3.1 Key Country Dynamics
      • 9.6.3.2 Regulatory Framework
      • 9.6.3.3 Pricing Analysis
      • 9.6.3.4 China Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.6.4 India
      • 9.6.4.1 Key Country Dynamics
      • 9.6.4.2 Regulatory Framework
      • 9.6.4.3 Pricing Analysis
      • 9.6.4.4 India Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.6.5 South Korea
      • 9.6.5.1 Key Country Dynamics
      • 9.6.5.2 Regulatory Framework
      • 9.6.5.3 Pricing Analysis
      • 9.6.5.4 South Korea Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.6.6 Australia
      • 9.6.6.1 Key Country Dynamics
      • 9.6.6.2 Regulatory Framework
      • 9.6.6.3 Pricing Analysis
      • 9.6.6.4 Australia Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.6.7 Thailand
      • 9.6.7.1 Key Country Dynamics
      • 9.6.7.2 Regulatory Framework
      • 9.6.7.3 Pricing Analysis
      • 9.6.7.4 Thailand Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.7 Latin America
    • 9.7.1 Latin America Vaccine Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 9.7.2 Brazil
      • 9.7.2.1 Key Country Dynamics
      • 9.7.2.2 Regulatory Framework
      • 9.7.2.3 Pricing Analysis
      • 9.7.2.4 Brazil Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.7.3 Argentina
      • 9.7.3.1 Key Country Dynamics
      • 9.7.3.2 Regulatory Framework
      • 9.7.3.3 Pricing Analysis
      • 9.7.3.4 Argentina Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.8 Middle East & Africa
    • 9.8.1 Middle East & Africa Vaccine Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 9.8.2 South Africa
      • 9.8.2.1 Key Country Dynamics
      • 9.8.2.2 Regulatory Framework
      • 9.8.2.3 Pricing Analysis
      • 9.8.2.4 South Africa Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.8.3 Saudi Arabia
      • 9.8.3.1 Key Country Dynamics
      • 9.8.3.2 Regulatory Framework
      • 9.8.3.3 Pricing Analysis
      • 9.8.3.4 Saudi Arabia Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.8.4 UAE
      • 9.8.4.1 Key Country Dynamics
      • 9.8.4.2 Regulatory Framework
      • 9.8.4.3 Pricing Analysis
      • 9.8.4.4 UAE Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.8.5 Kuwait
      • 9.8.5.1 Key Country Dynamics
      • 9.8.5.2 Regulatory Framework
      • 9.8.5.3 Pricing Analysis
      • 9.8.5.4 Kuwait Vaccine Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Participant Overview
  • 10.2. Company Market Position Analysis
  • 10.3. Company Categorization
  • 10.4. Strategy Mapping
  • 10.5. Company Profiles/Listing
    • 10.5.1 Serum Institute of India Pvt. Ltd.
      • 10.5.1.1 Overview
      • 10.5.1.2 Financial Performance
      • 10.5.1.3 Application Benchmarking
      • 10.5.1.4 Strategic Initiatives
    • 10.5.2 Seqirus
      • 10.5.2.1 Overview
      • 10.5.2.2 Financial Performance
      • 10.5.2.3 Application Benchmarking
      • 10.5.2.4 Strategic Initiatives
    • 10.5.3 Sanofi
      • 10.5.3.1 Overview
      • 10.5.3.2 Financial Performance
      • 10.5.3.3 Application Benchmarking
      • 10.5.3.4 Strategic Initiatives
    • 10.5.4 Merck & Co., Inc.
      • 10.5.4.1 Overview
      • 10.5.4.2 Financial Performance
      • 10.5.4.3 Application Benchmarking
      • 10.5.4.4 Strategic Initiatives
    • 10.5.5 Pfizer Inc.
      • 10.5.5.1 Overview
      • 10.5.5.2 Financial Performance
      • 10.5.5.3 Application Benchmarking
      • 10.5.5.4 Strategic Initiatives
    • 10.5.6 Moderna Inc.
      • 10.5.6.1 Overview
      • 10.5.6.2 Financial Performance
      • 10.5.6.3 Application Benchmarking
      • 10.5.6.4 Strategic Initiatives
    • 10.5.7 Sinovac
      • 10.5.7.1 Overview
      • 10.5.7.2 Financial Performance
      • 10.5.7.3 Application Benchmarking
      • 10.5.7.4 Strategic Initiatives
    • 10.5.8 BioNTech SE
      • 10.5.8.1 Overview
      • 10.5.8.2 Financial Performance
      • 10.5.8.3 Application Benchmarking
      • 10.5.8.4 Strategic Initiatives
    • 10.5.9 AstraZeneca
      • 10.5.9.1 Overview
      • 10.5.9.2 Financial Performance
      • 10.5.9.3 Application Benchmarking
      • 10.5.9.4 Strategic Initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global Vaccine Market, by Region, 2021 - 2033 (USD Million)
  • Table 4. Global Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 5. Global Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 6. Global Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 7. Global Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 8. Global Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 9. North America Vaccine Market, by Country, 2021 - 2033 (USD Million)
  • Table 10. North America Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 11. North America Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 12. North America Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 13. North America Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 14. North America Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 15. U.S. Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 16. U.S. Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 17. U.S. Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 18. U.S. Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 19. U.S. Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 20. Canada Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 21. Canada Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 22. Canada Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 23. Canada Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 24. Canada Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 25. Mexico Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 26. Mexico Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 27. Mexico Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 28. Mexico Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 29. Mexico Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 30. Europe Vaccine Market, by Country, 2021 - 2033 (USD Million)
  • Table 31. Europe Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 32. Europe Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 33. Europe Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 34. Europe Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 35. Europe Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 36. UK Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 37. UK Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 38. UK Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 39. UK Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 40. UK Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 41. Germany Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 42. Germany Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 43. Germany Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 44. Germany Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 45. Germany Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 46. France Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 47. France Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 48. France Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 49. France Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 50. France Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 51. Italy Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 52. Italy Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 53. Italy Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 54. Italy Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 55. Italy Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 56. Spain Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 57. Spain Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 58. Spain Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 59. Spain Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 60. Spain Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 61. Denmark Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 62. Denmark Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 63. Denmark Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 64. Denmark Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 65. Denmark Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 66. Norway Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 67. Norway Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 68. Norway Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 69. Norway Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 70. Norway Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 71. Sweden Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 72. Sweden Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 73. Sweden Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 74. Sweden Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 75. Sweden Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 76. Asia Pacific Vaccine Market, by Country, 2021 - 2033 (USD Million)
  • Table 77. Asia Pacific Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 78. Asia Pacific Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 79. Asia Pacific Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 80. Asia Pacific Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 81. Asia Pacific Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 82. Japan Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 83. Japan Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 84. Japan Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 85. Japan Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 86. Japan Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 87. China Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 88. China Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 89. China Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 90. China Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 91. China Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 92. India Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 93. India Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 94. India Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 95. India Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 96. India Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 97. South Korea Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 98. South Korea Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 99. South Korea Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 100. South Korea Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 101. South Korea Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 102. Australia Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 103. Australia Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 104. Australia Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 105. Australia Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 106. Australia Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 107. Thailand Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 108. Thailand Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 109. Thailand Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 110. Thailand Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 111. Thailand Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 112. Latin America Vaccine Market, by Country, 2021 - 2033 (USD Million)
  • Table 113. Latin America Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 114. Latin America Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 115. Latin America Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 116. Latin America Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 117. Latin America Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 118. Brazil Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 119. Brazil Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 120. Brazil Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 121. Brazil Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 122. Brazil Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 123. Argentina Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 124. Argentina Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 125. Argentina Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 126. Argentina Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 127. Argentina Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 128. Middle East & Africa Vaccine Market, by Country, 2021 - 2033 (USD Million)
  • Table 129. Middle East & Africa Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 130. Middle East & Africa Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 131. Middle East & Africa Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 132. Middle East & Africa Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 133. Middle East & Africa Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 134. South Africa Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 135. South Africa Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 136. South Africa Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 137. South Africa Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 138. South Africa Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 139. Saudi Arabia Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 140. Saudi Arabia Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 141. Saudi Arabia Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 142. Saudi Arabia Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 143. Saudi Arabia Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 144. UAE Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 145. UAE Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 146. UAE Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 147. UAE Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 148. UAE Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)
  • Table 149. Kuwait Vaccine Market, by Indication, 2021 - 2033 (USD Million)
  • Table 150. Kuwait Vaccine Market, by Type, 2021 - 2033 (USD Million)
  • Table 151. Kuwait Vaccine Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 152. Kuwait Vaccine Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 153. Kuwait Vaccine Market, by Distribution Channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Vaccine Market outlook
  • Fig. 14 Vaccine Market competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Vaccine Market driver impact
  • Fig. 20 Vaccine Market restraint impact
  • Fig. 21 Vaccine Market strategic initiatives analysis
  • Fig. 22 Vaccine Market Indication movement analysis
  • Fig. 23 Vaccine Market Indication outlook and key takeaways
  • Fig. 24 Viral Vaccine market estimates and forecast, 2021 - 2033
  • Fig. 25 Hepatitis market estimates and forecast, 2021 - 2033
  • Fig. 26 Influenza market estimates and forecast, 2021 - 2033
  • Fig. 27 HPV market estimates and forecast, 2021 - 2033
  • Fig. 28 MMR market estimates and forecast, 2021 - 2033
  • Fig. 29 Rotavirus market estimates and forecast, 2021 - 2033
  • Fig. 30 Herpes Zoster market estimates and forecast, 2021 - 2033
  • Fig. 31 Japanese Encephalitis market estimates and forecast, 2021 - 2033
  • Fig. 32 RSV market estimates and forecast, 2021 - 2033
  • Fig. 33 Others market estimates and forecasts, 2021 - 2033
  • Fig. 34 Bacterial Vaccine market estimates and forecast, 2021 - 2033
  • Fig. 35 Meningococcal Diseases market estimates and forecast, 2021 - 2033
  • Fig. 36 Pneumococcal diseases market estimates and forecast, 2021 - 2033
  • Fig. 37 DPT market estimates and forecast, 2021 - 2033
  • Fig. 38 Others market estimates and forecasts, 2021 - 2033
  • Fig. 39 Cancer Vaccine market estimates and forecast, 2021 - 2033
  • Fig. 40 Pediatric (Children) market estimates and forecast, 2021 - 2033
  • Fig. 41 Adult market estimates and forecast, 2021 - 2033
  • Fig. 42 Allergy Vaccine market estimates and forecast, 2021 - 2033
  • Fig. 43 Pediatric (Children) market estimates and forecast, 2021 - 2033
  • Fig. 44 Adult market estimates and forecast, 2021 - 2033
  • Fig. 45 Other market estimates and forecast, 2021 - 2033
  • Fig. 46 Pediatric (Children) market estimates and forecast, 2021 - 2033
  • Fig. 47 Adult market estimates and forecast, 2021 - 2033
  • Fig. 48 Vaccine Market Type movement analysis
  • Fig. 49 Vaccine Market Type outlook and key takeaways
  • Fig. 50 Subunit Vaccine market estimates and forecast, 2021 - 2033
  • Fig. 51 Recombinant Vaccine market estimates and forecast, 2021 - 2033
  • Fig. 52 Conjugate Vaccine market estimates and forecast, 2021 - 2033
  • Fig. 53 Toxoid Vaccine market estimates and forecast, 2021 - 2033
  • Fig. 54 Inactivated market estimates and forecasts, 2021 - 2033
  • Fig. 55 Live Attenuated market estimates and forecast, 2021 - 2033
  • Fig. 56 mRNA Vaccine market estimates and forecast, 2021 - 2033
  • Fig. 57 Viral Vector Vaccine market estimates and forecast, 2021 - 2033
  • Fig. 58 Vaccine Market Route of Administration movement analysis
  • Fig. 59 Vaccine Market Route of Administration outlook and key takeaways
  • Fig. 60 Oral market estimates and forecast, 2021 - 2033
  • Fig. 61 Parenteral market estimates and forecast, 2021 - 2033
  • Fig. 62 Nasal market estimates and forecast, 2021 - 2033
  • Fig. 63 Vaccine Market Age Group movement analysis
  • Fig. 64 Vaccine Market Age Group outlook and key takeaways
  • Fig. 65 Pediatric market estimates and forecast, 2021 - 2033
  • Fig. 66 Adult market estimates and forecast, 2021 - 2033
  • Fig. 67 Vaccine Market Distribution Channel movement analysis
  • Fig. 68 Vaccine Market Distribution Channel outlook and key takeaways
  • Fig. 69 Hospital & Retail Pharmacies market estimates and forecast, 2021 - 2033
  • Fig. 70 Government Suppliers market estimates and forecast, 2021 - 2033
  • Fig. 71 Others market estimates and forecasts, 2021 - 2033
  • Fig. 72 Vaccine Market Regional movement analysis
  • Fig. 73 Vaccine Market Regional outlook and key takeaways
  • Fig. 74 Vaccine Market share and leading players
  • Fig. 75 North America Vaccine Market share and leading players
  • Fig. 76 Europe Vaccine Market share and leading players
  • Fig. 77 Asia Pacific Vaccine Market share and leading players
  • Fig. 78 Latin America Vaccine Market share and leading players
  • Fig. 79 Middle East & Africa Vaccine Market share and leading players
  • Fig. 80 North America Vaccine Market SWOT Analysis
  • Fig. 81 Europe Vaccine Market SWOT Analysis
  • Fig. 82 Asia Pacific Vaccine Market SWOT Analysis
  • Fig. 83 Latin America Vaccine Market SWOT Analysis
  • Fig. 84 Middle East & Africa Vaccine Market SWOT Analysis
  • Fig. 85 North America Vaccine Market Analysis, by country
  • Fig. 86 North America
  • Fig. 87 North America Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 88 US
  • Fig. 89 US Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 90 Canada
  • Fig. 91 Canada Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 92 Mexico
  • Fig. 93 Mexico Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 94 Europe
  • Fig. 95 Europe Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 96 UK
  • Fig. 97 UK Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 98 Germany
  • Fig. 99 Germany Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 100 France
  • Fig. 101 France Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 102 Italy
  • Fig. 103 Italy Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 104 Spain
  • Fig. 105 Spain Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 106 Denmark
  • Fig. 107 Denmark Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 108 Sweden
  • Fig. 109 Sweden Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 110 Norway
  • Fig. 111 Norway Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 112 Asia Pacific
  • Fig. 113 Asia Pacific Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 114 China
  • Fig. 115 China Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 116 Japan
  • Fig. 117 Japan Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 118 India
  • Fig. 119 India Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 120 Thailand
  • Fig. 121 Thailand Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 122 South Korea
  • Fig. 123 South Korea Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 124 Australia
  • Fig. 125 Australia Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 126 Latin America
  • Fig. 127 Latin America Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 128 Brazil
  • Fig. 129 Brazil Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 130 Argentina
  • Fig. 131 Argentina Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 132 Middle East & Africa
  • Fig. 133 Middle East & Africa Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 134 South Africa
  • Fig. 135 South Africa Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 136 Saudi Arabia
  • Fig. 137 Saudi Arabia Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 138 UAE
  • Fig. 139 UAE Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 140 Kuwait
  • Fig. 141 Kuwait Vaccine Market Estimates and Forecasts 2021 - 2033
  • Fig. 142 Market share of key market players - Vaccine Market